Table of Contents

Ozempic pens have become one of the most widely used medications for diabetes and weight management. For many people, it delivers real benefits with manageable side effects.

As more patients use the drug, new questions are emerging. Some individuals report episodes of anxiety, nervousness, or panic after starting treatment, while others notice no mental health changes at all. These mixed experiences have sparked debate among clinicians and researchers alike.

Importantly, Ozempic was not designed to act on mood or anxiety. Yet the drug works through GLP-1 receptors, which are present not only in metabolic tissues but also in parts of the brain involved in stress signaling and autonomic regulation. That overlap has led scientists to explore whether certain people might be more sensitive to these effects.

So what do studies actually show? Can Ozempic cause anxiety and panic attacks?

Key Takeaways

  • Clinical trials of Ozempic found no increase in anxiety or depression vs placebo.
  • Large real-world studies show mixed results. Some found a higher anxiety risk on GLP-1 drugs, while others found no higher risk and found improvements in depression scores instead.
  • Regulators have noted reports of mood changes in GLP-1 users, but have not confirmed a causal link.
  • If you experience significant anxiety or panic attacks on Ozempic, talk to your doctor. It may be due to medication interactions, lifestyle factors, or other causes rather than Ozempic itself. Managing these symptoms is important for your safety and comfort.

What are anxiety and panic disorders?

Anxiety is a broad term for excessive worry, nervousness, or fear that is often out of proportion to actual events. Common symptoms include:

    • Restlessness
    • Tension
    • Racing thoughts
    • Insomnia
    • Physical signs like muscle tightness or stomach upset

Panic attacks are intense bursts of fear that reach a peak within minutes. During a panic attack, a person may feel:

    • A racing or pounding heart (palpitations), chest pain or tightness
    • Shortness of breath or a choking sensation
    • Trembling, sweating, or chills
    • A sense of impending doom or fear of losing control

These symptoms often mimic medical emergencies like a heart attack, and they can be very frightening. After the attack subsides, people often feel exhausted or shaken.

Anxiety and panic attacks are recognized psychiatric conditions. They can occur by themselves (panic disorder) or as part of broader anxiety, stress, or mood disorders.

Patient reports about “Ozempic Personality”

Stressed out overweight man

As Ozempic and other GLP-1 weight loss drugs have grown in popularity, patient anecdotes of mood changes have surfaced.

On social media and in news stories, some people have described feeling more anxious, overwhelmed, or depressed after starting Ozempic or its sister drug, Wegovy. A news report shared the story of one diabetic woman who began using Ozempic and soon felt “constantly in a state of being overwhelmed… crying all the time”.

Such reports have even been dubbed “Ozempic personality” in headlines, referring to a cluster of symptoms that some users attribute to GLP-1 drugs, including:

    • Increased anxiety
    • Depression
    • Emotional flatness

These stories have caught media attention, but they do not prove cause and effect. It’s possible that individuals predisposed to anxiety notice their symptoms during weight loss. Still, the volume of anecdotes pushed regulators to review the issue.

By mid-2023, the European Medicines Agency (EMA) opened a formal review after about 150 reports of suicidal thoughts and self-harm linked to GLP-1 drugs. As the EMA noted, it was unclear whether these cases were due to the drugs or underlying conditions.

The US Food and Drug Administration (FDA) has also been investigating reports, but they currently do not see clear evidence that these drugs cause suicidal thoughts or actions. They reviewed three main sources:

  • Reports from real patients (FAERS) – These are voluntary reports from patients, doctors, and pharmacists. Many reports did not include enough detail, and mental health events can be influenced by other factors, such as:
        • A history of depression or anxiety
        • Life stress
        • Weight-related stigma
        • Other medications
    Because of this, the FDA said the reports did not show a clear cause-and-effect relationship.
  • Clinical trials – They reviewed data from:
        • Randomized clinical trials
        • Large cardiovascular outcome studies
        • Observational studies
    Result showed that the rates of suicidal thoughts were similar in people taking GLP-1 drugs and those taking a placebo or other treatments.
  • Large database studies (ongoing) – The FDA is still working on:
      • A meta-analysis combining many trials
      • An analysis using the Sentinel System, which pulls from massive insurance and medical record databases
    Because these analyses are ongoing, the FDA says they cannot fully rule out a very small risk yet.

Some social-media analyses found mixed reports. Among all the posts analyzed, the most common themes were:

    • Sleep problems, especially insomnia (620 mentions)
    • Anxiety (353 mentions)
    • Depression (204 mentions)
    • General mental health concerns (165 mentions)

People reported:

    • Mood improving for some, worsening for others
    • Anxiety and insomnia either increasing or decreasin
    • Better control over addictive behaviors in some users (for example food cravings or compulsive habits)

In other words, the same drug was linked to opposite effects in different people. This variability suggests that different people react differently, and that factors like personal history and context likely matter.

Can Ozempic cause anxiety?

While anecdotes raise questions, what do formal studies show?

A pooled analysis of the large Phase 3 STEP weight loss trials included people without major pre-existing psychiatric disorders. Results found no increase in depression or suicidal thoughts with semaglutide compared to placebo.

In those trials, PHQ-9 depression scores actually improved slightly on semaglutide.

For example, anxiety-related events occurred in about 3.3% of the semaglutide group versus 4.2% of placebo in pooled STEP 1/2/3. In STEP 5, semaglutide users had 7.2% anxiety events vs 9.2% on placebo.

Real-world patient populations differ from trial subjects, so researchers have also examined observational data.

A 2023 study using US medical records compared thousands of people on semaglutide to matched patients on other diabetes medications like sitagliptin, empagliflozin, and glipizide. Over 12 months, there was no higher risk of psychiatric or neurological problems in the semaglutide group.

In fact, semaglutide users had lower rates of some issues, like cognitive decline, compared to alternatives. The authors concluded that semaglutide was not linked to increased neuropsychiatric risk, including anxiety or depression.

Another large retrospective analysis looked specifically at suicidal thoughts in obese or diabetic patients. In over 240,000 adults with overweight or obesity, those on semaglutide had a much lower risk of new or recurring suicidal ideation than matched patients on other weight-loss or anti-diabetes drugs.

A similar finding was held in a separate cohort of patients with diabetes. Semaglutide users were about 70% less likely to report suicidal thoughts over six months than other treated patients.

On the other hand, a 2024 cohort study from Taiwan, with over 160,000 patients, found that GLP-1 drugs (semaglutide and liraglutide) were associated with higher psychiatric risks. After careful matching, GLP-1 users had about double the odds of any psychiatric disorder, a nearly 3-fold higher risk of major depression, and a ~108% higher risk of anxiety than controls.

A pharmacovigilance analysis using VigiBase, the WHO’s adverse event database, looked at 2 million reported adverse drug reactions for GLP-1 drugs. For semaglutide, anxiety was reported 26% more often than expected. The same analysis found higher-than-expected reports of depressed mood (70%) and suicidal ideation (45%) with semaglutide.

Conversely, a recently published study (2026) concluded that GLP-1 drugs do not appear to cause or increase psychiatric disorders, including depression and suicidal thoughts or behavior.

How does Ozempic influence anxiety?

Researchers have proposed several ways Ozempic might affect anxiety in some people.

Possible direct effects on the brain

Given the mixed evidence, researchers are exploring possible mechanisms for how Ozempic could affect mood. One hypothesis is direct brain effects.

GLP-1 receptors are present in several brain regions involved in appetite, reward, and emotions. Animal and lab studies suggest that GLP-1 drugs can influence brain chemicals tied to mood and motivation, and may help the brain form new cells in areas involved in emotion.

For example, in a mouse model of diabetes, the mice that received semaglutide showed:

    • Less depression-like behavior
    • Less anxiety-like behavior
    • Improved cognitive performance
    • Healthier brain signaling
    • Reduced inflammation in the hippocampus (a vital brain area for mood and memory)
    • Better communication between brain cells
    • Increased serotonin (a mood-related neurotransmitter), including the proteins involved in serotonin transport, and the receptors involved in learning and memory

These are changes often linked with antidepressant effects.

Changes in reward and emotional processing

Biological effects can vary by context. It’s been noted that by strongly suppressing appetite and reducing pleasure from food, GLP-1 drugs might inadvertently blunt other sources of joy. Some patients describe an “emotional dullness” when full satisfaction from eating is lost.

This shift in reward balance could theoretically unmask or worsen underlying anxiety or low mood in susceptible people. In other words, if the brain’s usual reward stimuli (like tasty foods) become less important, other neural pathways may dominate feelings. However, this theory remains speculative and likely applies only to some individuals.

Physical side effects that can feel like anxiety

Another possibility involves stress from the physical side effects. Chronic nausea or gastrointestinal discomfort on Ozempic can make anyone feel anxious or irritable over time. Likewise, concerns about low blood sugar can cause worry.

If a patient experiences palpitations or lightheadedness, they might mistake that for a panic attack. It’s worth noting that Ozempic itself does not trigger panic biologically, but it can create sensations that mimic panic.

Psychological stress during rapid weight loss

Losing a lot of weight quickly can bring unexpected psychological challenges. Some people feel stressed about maintaining the loss, or they become anxious about how others perceive them. They may experience body image issues or shifting identity.

These psychosocial factors are hard to measure but could contribute to anxiety, especially in people already vulnerable.

The role of obesity and diabetes

Finally, obesity and diabetes themselves are linked to anxiety. Both conditions carry stigma and chronic stress.

In a sample of 732 overweight and obese adults, both anxiety and depression were more common in individuals with higher body mass index (BMI). Patients with anxiety or depression had significantly higher BMI and percentage of body fat compared with those without these conditions.

Anxiety was more prevalent in female participants, and both anxiety and depression occurred more frequently among housekeepers. Sleep duration was not associated with weight status or with the presence of anxiety or depression. Overall, the results indicate a strong bidirectional relationship between obesity and anxiety or depressive symptoms, independent of sleep behavior.

In a separate study, individuals with diabetes reported higher levels of depressive symptoms and generalized anxiety and lower health-related quality of life (HRQOL) compared with non-diabetic individuals.

Among participants with diabetes, those who were obese showed the highest rates of depression and anxiety and the lowest HRQOL scores.

Analyses showed that BMI partially explained the association between diabetes and both depression and anxiety, while health-related quality of life fully mediated these relationships. These results indicate that poorer quality of life and higher body weight substantially account for the increased burden of depression and anxiety seen in people with diabetes.

Managing anxiety and panic on Ozempic

Although most people tolerate Ozempic well, anxiety or panic may occur in some individuals and should be addressed promptly.

Take new or worsening symptoms seriously

Any new or worsening anxiety, panic, or low mood while taking Ozempic should be addressed promptly. If you feel jittery, panicky, or emotionally distressed, inform your healthcare provider.

Clinicians will first look for medical explanations, such as side effects or low blood sugar. Checking blood glucose during an anxiety episode can also help identify unrecognized hypoglycemia. If palpitations are present, monitoring heart rate or further cardiac evaluation may be appropriate.

Adjusting treatment if anxiety persists

If anxiety appears linked to Ozempic, several adjustments may help. For some patients, symptoms lessen as the body adapts over time. If not, a clinician may reduce the dose, switch to a different GLP-1 medication, or consider non-GLP-1 weight loss options.

Addressing lifestyle factors is also important. Regular meals, adequate hydration, and avoiding skipped meals can reduce blood sugar fluctuations that worsen anxiety. Exercise, sleep hygiene, and stress-management practices such as mindfulness may further support emotional stability. In some cases, therapy or anti-anxiety medication may be considered.

Clinical monitoring and caution

Healthcare professionals are aware of potential mood-related concerns with GLP-1 therapies. Regulatory guidance encourages monitoring for changes in mood or behavior and screening for prior psychiatric history before starting treatment.

While current evidence does not clearly show that Ozempic causes anxiety, a cautious and individualized approach helps ensure your safety. Early recognition allows intervention before symptoms escalate.

Bottom line

At this point, it is fair to say that we do not have a definitive answer. The evidence is mixed and somewhat conflicting. Ongoing studies and patient registries may clarify whether Ozempic truly increases anxiety risk, or if the reports reflect the complexities of obesity, diabetes, and rapid weight change.

In the meantime, the safest position is to be aware of the potential. If you are on Ozempic and notice unusual anxiety or panic-like episodes, seek medical advice. Your doctor can help determine the cause, whether it’s Ozempic-related or not, and guide you to feel safe and supported while pursuing your health goals.

Related Articles

Frequently Asked Questions

If anxiety appears after starting Ozempic, talk to your healthcare provider. Anxiety-like symptoms may improve with a slower dose increase, dose reduction, or better blood sugar stability. Eating regularly, staying hydrated, and avoiding excess caffeine can help. If the symptoms continue, your provider may suggest switching medications or adding mental health support.

Common side effects include nausea, vomiting, diarrhea, constipation, and reduced appetite. Some people experience dizziness, fatigue, or headaches, especially during dose increases. Rare but serious risks include pancreatitis and gallbladder problems. Side effects are more likely when doses are raised too quickly.

Anxiety and low mood have been reported by some patients. These symptoms may be related to blood sugar changes, appetite suppression, or individual sensitivity. Large clinical trials did not show high rates of diagnosed anxiety or depression. Still, any new mental health symptoms should be discussed with a clinician.

Ozempic does not directly damage the nervous system. It works mainly through hormone pathways that affect appetite, insulin release, and digestion. However, changes in blood glucose or stress hormones may indirectly influence how some people feel mentally or physically. This can lead to symptoms like jitteriness or restlessness in sensitive individuals.

Social anxiety is not a known direct side effect of Ozempic. Some people may feel more self-conscious or withdrawn due to nausea, fatigue, or mood changes. Appetite changes and weight loss can also affect social eating situations. If social anxiety develops, it is important to explore other contributing factors with a provider.

Ozempic can usually be stopped without tapering, but this should be done with medical guidance. Blood sugar levels and appetite may rise after stopping. People using it for diabetes may need an alternative treatment right away. Stopping suddenly does not cause withdrawal, but symptoms that the drug was controlling may return.

Some people stop because of ongoing side effects like nausea or digestive discomfort. Others stop due to cost, insurance coverage issues, or supply shortages. Weight regain after stopping is also a concern for some patients. Mental or emotional side effects may also lead certain individuals to discontinue treatment.

If you miss two weeks, you may need to restart at a lower dose to reduce side effects. Skipping doses can cause blood sugar levels or appetite to increase again. Do not double up on doses to catch up. Always follow your prescriber’s instructions for restarting.

Ozempic should be stopped if you develop severe side effects such as ongoing vomiting, signs of pancreatitis, or allergic reactions. It may also be discontinued if mental health symptoms become persistent or disruptive. Lack of benefit or inability to tolerate the medication are common reasons to stop. Decisions should always be made with a healthcare professional.

Some users report mood changes, irritability, or emotional sensitivity while on Ozempic. These effects are not common but can occur. Changes in eating patterns, blood sugar, or stress hormones may contribute. Emotional symptoms should be monitored and discussed if they persist.

Aggression is not a listed or well-documented side effect of Ozempic. However, irritability or mood changes may be mistaken for aggressive behavior in some cases. Hunger changes or low blood sugar can worsen frustration in certain people. Any sudden personality changes should be evaluated by a clinician.

Mood swings have been reported anecdotally, though they are not among the most common side effects. Fluctuations in blood sugar, appetite suppression, or stress around eating may contribute. Most people do not experience major mood instability. Persistent mood changes should be medically assessed.

Sources

Arillotta, D., Floresta, G., Guirguis, A., Corkery, J. M., Catalani, V., Martinotti, G., Sensi, S. L., & Schifano, F. (2023). GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sciences, 13(11), 1503. https://doi.org/10.3390/brainsci13111503

EMA statement on ongoing review of GLP-1 receptor agonists | European Medicines Agency (EMA). (2023, July 11). European Medicines Agency (EMA). https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists

FDA. (2026, January 13). Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. U.S. Food And Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type

Lupkin, S. (2023, September 21). As Ozempic use grows, so do reports of possible mental health side effects. TPR. https://www.tpr.org/bioscience-medicine/2023-09-21/as-ozempic-use-grows-so-do-reports-of-possible-mental-health-side-effects

The mental health effects of Ozempic and GLP-1 drugs | Think Global Health. (2025, December 4). Think Global Health. https://www.thinkglobalhealth.org/article/the-mental-health-effects-of-ozempic-and-glp-1-drugs

Wadden, T. A., Brown, G. K., Egebjerg, C., Frenkel, O., Goldman, B., Kushner, R. F., McGowan, B., Overvad, M., & Fink-Jensen, A. (2024). Psychiatric safety of semaglutide for weight management in people without known major psychopathology. JAMA Internal Medicine, 184(11), 1290. https://doi.org/10.1001/jamainternmed.2024.4346

De Giorgi, R., Koychev, I., Adler, A. I., Cowen, P. J., Harmer, C. J., Harrison, P. J., & Taquet, M. (2024). 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. EClinicalMedicine, 74, 102726. https://doi.org/10.1016/j.eclinm.2024.102726

Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024). Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nature Medicine, 30(1), 168–176. https://doi.org/10.1038/s41591-023-02672-2

Kornelius, E., Huang, J., Lo, S., Huang, C., & Yang, Y. (2024). The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Scientific Reports, 14(1), 24433. https://doi.org/10.1038/s41598-024-75965-2

Nishida, K., Chrétien, B., Dolladille, C., Ebina, T., Aleksic, B., Cabé, N., Savey, V., Onoue, T., & Yatsuya, H. (2025). Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A vigibase study. Clinical Nutrition, 51, 252–265. https://doi.org/10.1016/j.clnu.2025.06.011

Farokhnia, M., & Leggio, L. (2026). Prospects of GLP-1 Therapies for Addiction and Mental Health Comorbidities—Quo Vadis? JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2025.4308

Sharafi, S. E., Garmaroudi, G., Ghafouri, M., Bafghi, S. A., Ghafouri, M., Tabesh, M. R., & Alizadeh, Z. (2019). Prevalence of anxiety and depression in patients with overweight and obesity. Obesity Medicine, 17, 100169. https://doi.org/10.1016/j.obmed.2019.100169

Herhaus, B., Kruse, J., Hinz, A., Brähler, E., & Petrowski, K. (2024). Depression, anxiety, and health-related quality of life in normal weight, overweight and obese individuals with diabetes: a representative study in Germany. Acta Diabetologica, 61(6), 725–734. https://doi.org/10.1007/s00592-024-02248-7

De Paiva, I. H. R., Da Silva, R. S., Mendonça, I. P., De Souza, J. R. B., & Peixoto, C. A. (2024). Semaglutide attenuates anxious and Depressive-Like behaviors and reverses the cognitive impairment in a type 2 diabetes mellitus mouse model via the Microbiota-Gut-Brain axis. Journal of Neuroimmune Pharmacology, 19(1), 36. https://doi.org/10.1007/s11481-024-10142-w